Short Term Sirolimus Treatment and MRI of the Brain
Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
Alzheimer's disease is a devastating neurodegenerative disease characterized by accumulation
of clumps (also called plaques) and bundles of fibers (also called tangles) in the brain, for
which there is currently no cure. Sirolimus is an FDA-approved medication which may improve
the blood flow to the brain. This study is designed to see if sirolimus treatment improves
MRI blood flow to the brain in individuals with and without a genetic predisposition to
Alzheimer's disease.